Decitabine is a synthetic nucleoside that can significantly slow the progression of acute myeloid leukaemia (AML) through an epigenetic mechanism that is not fully understood. However, this is not seen in all patients and toxic side effects are common. Preliminary work in WP1 has shown that decitabine can be chemically modified to increase its stability and reduce unwanted side effects. The aim of this WP is to develop decitabine analogs with even better pharmacological properties.